Related U.S. Application Data (62) Division of application No. 1 1/822,786, filed on Jul. 10, 2007, now Pat. No. 7,763,255 , which is a division of application No. 10/668,601, filed on Sep. 24, 2003, now Pat. No. 7,264,813. (51) Int. Cl. (56) References Cited U.S. PATENT DOCUMENTS PP4,511 P 3, 1980 Avron et al. 4,199,895 A 4, 1980 Avron et al. 4.915,965 A 4, 1990 Tanaka 5, 190,970 A 3, 1993 Panet al. 5,219,888 A 6/1993 Katocs, Jr. et al. 5,304,575 A 4, 1994 . Beck 5.948,823. A 9, 1999 Ben-Amotz et al. tene content comprises about 50% all-trans-B-caroteine with the remainder composed mostly of 9-cis B-carotene and a few otherf-carotene isomers''. A process has been described for cultivating D. bardawill so as to obtain algae containing up to about 5% by weight of B-carotene'. Later developments of the process increased the percentage to more than 8%. It has been shown that the natural isomer mixture of B-carotene which is accumulated in the alga Dunaliella bardawil is accu mulated in fatty tissues of rats and chicks to an extent which is about 10 fold higher than that observed by feeding the synthetic all-trans B-carotene'.
Various carotenoid-enriched Dunaliella commercial prod ucts are available such as BetateneTM (produced by the Hen kel Corp., Germany) and NutriliteTM (Amway, Inc., U.S.A.). These products are oil extracts of carotenoids from Dunaliella. Retinoids are essential for a living organism for vision, cellular growth, differentiation, and to maintain the general health of the organism. 9-cis-retinoic-acid and all-trans-ret inoic-acid are produced in the body by the cleavage of B-caro tene (BC). The retinoid nuclear receptors, also known as orphan receptors RAR and RXR, have distinct physiologic properties by activating transcriptional factors. All-trans ret inoic-acid binds to RAR but not to RXR, while 9-cis retinoic acid binds to RXR, which plays a key role in important biological processes.
The activation of nuclear receptors is essential to cell metabolism, especially with respect to lipids and glucose. Several nuclear receptors have been implicated in cholesterol homeostasis. These receptors include: the liver X receptors (LXRa/NR1H3 and LXRb/NR1H2) and farnesoid X receptor (FXR/NR1H4) that are bound and activated by oxysterols and bile acids, respectively. LXR and FXR form obligate het erodimers with RXR that is activated by 9-cis retinoic acid and synthetic agonists (termed rexinoids). It was recently found that the activation of RXR by its ligands can affect two central processes of cholesterol metabolism: I. Cholesterol absorption in the intestine (activation of RXR/FXR het erodimer repressed cholesterol 7O-hydroxylase (CYP7A1) expression, resulting in decreased bile acid synthesis and cholesterol absorption). II. Reverse cholesterol transport from peripheral tissues (activation of RXR/LXRheterodimer inhibited cholesterol absorption and induced reverse choles terol transport in peripheral tissues).
The following nuclear receptors are known to form het erodimers with RXR and hence, can be potentially activated by 9-cis retinoic acid administration: thyroid hormone (TRa/ b); vitamin D (VDR); fatty acid/eicosanoids (PPARC/BY); oxysterols (LXRa/b); bile acids (FXR); pregnanes/bile acids/ xenobiotics (PXR); androstanes/xenobiotics (CAR).
Fibrates (clofibrate, fenofibrate, bezafibrate, ciprofibrate, beclofibrate and gemfibrozil) are currently recommended for the treatment of patients with hypertriglyceridemia (high plasma TG). The treatment of hypertriglycerdemia results in decreased plasma levels of triglyceride-rich lipoproteins. HDL cholesterol levels are usually increased when the base line levels are low. The increase in HDL cholesterol is usually concomitant with increased levels of the HDL apolipoprotein A-I and A-II. In addition, fibrates reduce the atherogenic apoC-III-containing particles, effect post-prandial lipemia and some fibrate lower plasma fibrinogen and CRP levels.
As a consequence of their effect on lipid metabolism, fibrates have been shown to affect specific lipoprotein disor ders such as in combined hyperlipidemia, primary hypertrig lyceredemia, type III dysbetalipoprotenemia, and non-insulin dependent diabetes mellitus (NIDDM).
Fibrates are considered to be well tolerated, with an excel lent safety profile. A low toxicity has been reported in almost every organ system. Fenofibrate treatment revealed low fre quency of side effects. Long-term administration revealed no effect on peroxisome proliferation in human liver and no evidence for carcinogenesis. Clinically relevant interaction of fibrates with other anti-hyperlipedemic drugs include rhab domyolysis and decreased bioavailibility when combined with some bile acid sequestrants. Potentiation of the antico agulant effect of coumarin may cause bleeding.
Fibrates mediate at least part of their effects by peroxisome proliferator-activated receptor C. (PPAR-O.). Upon activation with fibrates, PPARs heterodimerize with another nuclear receptor, the 9-cis retinoic acid receptor (RXR). The dimer binds to specific response elements, termed peroxisome pro liferator response elements (PPREs) and regulates gene expression.
Low plasma levels of high-density lipoprotein (HDL) and high triglyceride (TG) plasma levels are risk factors for ath erosclerosis. Low levels of plasma HDL cholesterol, apoli poprotein AI (apoA-I) and high levels of triglycerides (TG) are associated with increased risk for atherosclerosis, the major cause of morbidity and mortality in Western societies. A recent study showed that the rate of coronary events is 3 reduced by 22 percent by raising HDL cholesterol levels and lowering the plasma TG levels in patients treated with the fibrate gemfibrozil.
Several modes of action were proposed for the fibrate ben eficial effects on atherosclerosis: Induction of lipoprotein lipolysis by reducing apoC-III levels and/or by increasing lipoprotein lipase activity. Induction of hepatic fatty acid (FA) uptake by the induction of FA-transporter protein and acyl CoA synthetase. Decrease apoB and VLDL production. Reduction of hepatic TG production by induction of peroxi Some (in rodents only) or mitochondrial B-Oxidation pathway and inhibition of FA synthesis. Most important, fibrates increase the production of apoA-I and apoA-II in the liver, which probably contribute to the process of reverse choles terol transport.
Type 2 diabetes mellitus is a serious health problem. It arises when resistance to the glucose lowering effects of insulin combines with impaired insulin secretion to raise the levels of glucose in the blood beyond the normal range. Thia Zolidinediones are a new class of antidiabetic agents that improve insulin sensitivity and reduce plasma glucose and blood pressure in subjects with type 2 diabetes'. The drugs bind and activate PPARY that binds to DNA as heterodimers with a common partner, retinoid X receptor (RXR) to regulate transcription. RXR agonists have been shown to function as insulin sensitizers, markedly decreasing serum glucose, trig lycerides and insulin in obese mice'.
WO93/24454 describes a carotenoid composition derived from Dunaliella algae in which the B-carotene content is predominantly 9-cis B-carotene. There is no mention of any medical applications.
U.S. Pat. No. 5.219.888 (Katocs) discloses a method to increase plasma HDL levels for the treatment and prevention of coronary artery disease by administrating a therapeutic amount of the retinoids all trans-retinoic acid and 9-cis-ret inoic acid. U.S. Pat. No. 5.948,823 discloses use of a substantially crude Dunaliella algae preparation in protecting mammals against the detrimental effects of medical and nuclear irradia tion.
WO 97/10819 teaches a new treatment for non-insulin dependent diabetes mellitus by administration of RXR ago nists and optionally, peroxisome proliferation activated receptor gamma agonists. WO 99/50658 identifies compounds which modulate nuclear receptor activity, used for treating e.g. cancer, cardio vascular disease, osteoporosis, diabetes, postmenopausal dis orders and inflammatory conditions. WO 2001 119770 reveals new retinoid Xanalogs, useful as retinoid X receptor modulators for lowering blood glucose levels, for modulating lipid metabolism and in treatment of e.g. diabetes, obesity, cardiovascular diseases and breast can C.
U.S. Pat. Nos. 5,972,881 and 6,028,052 (Heyman) disclose methods and compositions for the treatment of non-insulin dependent diabetes using an RXR agonist together with a PPARY agonist.
WO 03/027090 provides novel retinoid compounds that have selectivity as RXR agonists, and are effective in reduc ing blood glucose and maintaining body weight, thus being useful for the treatment of diabetes (NIDDIM) and obesity.
Colagiuri S. and Best, J. Lipid-lowering therapy in people with type 2 diabetes. Current Opinion in Lipidology (2002) 13:617-623, teaches that lipid powering with statins and fibrates is effective in improving cardiovascular disease out come in diabetes. 
SUMMARY OF THE INVENTION
It is an object of the invention to provide a method for treating patients suffering from diabetes, low plasma HDL and/or high plasma TG and/or atherosclerosis.
The present invention provides by one of its aspects, a method for treating a disease selected from diabetes mellitus and atherosclerosis comprising administrating to a Subject an effective amount of crude Dunaliella powder.
The present invention also provides by another aspect a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a Subject comprising administrating to the Subject an effective amount of crude Dunaliella powder.
In accordance with another aspect of the invention there is provided a medicament for use in treating diabetes mellitus, low plasma HDL and/or high plasma TG and/or atheroscle rosis, comprising an effective amount of a substantially crude Dunaliella algae preparation.
In accordance with a further aspect of the invention, there is provided the use of an effective amount of a substantially crude Dunaliella algae preparation in the preparation of a pharmaceutical composition for use in treating diabetes mel litus, low plasma HDL and/or high plasma TG and/or athero
Sclerosis
The active ingredient in accordance with the invention is a Substantially crude Dunaliella algae preparation, typically dried Dunaliella algae. The Dunaliella algae are preferably Dunaliella bardawil.
The terms "treating or "treatment in the present specifi cation should be understood as including both the curing of the disease, as well as bringing about an improvement in the pathological symptoms of the disease. The terms may also include prevention of the diseases. These terms also relate to the potential to inhibit both the initiation and progression of atherosclerosis and to the reduction of inflammation, thereby inhibiting and preventing complications of the disease.
An "effective amount' should be understood as an amount or dose of the active ingredient which is sufficient to achieve the desired therapeutic effect, i.e. treatment of the indicated diseases. The effective amount depends on various factors including the severity of the disease, the administration regi men, e.g. whether the preparation is given once or several times over a period of time, the physical condition of the subject; etc. The artisan should have no difficulties, by mini mal experiments, to determine the effective amount in each CaSC.
The term "atherosclerosis" includes all types of the disease including calcified plaques, non-calcified plaques, fibrocal cified plaques and others. The term "diabetes' includes all types of diabetes, in particular type 2 diabetes mellitus.
In a preferred embodiment, the crude Dunaliella powder is administered together with one or more activators of nuclear receptors. The activators of nuclear receptors are preferably peroxisome proliferator-activated receptor C. and Y (PPARC. and PPARY) agonists, such as fibrates and thiazolidinediones. In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be 10 described, by way of non-limiting example only, with refer ence to the accompanying drawings, in which: 
DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION 30
Methods and Materials
All of the human studies described below employed cap Sules containing Dunaliella powder prepared as follows.
Dunaliella bardawill (hereinafter "Db') was grown and 35 cultivated in large body open saltwater ponds of 50,000 m to obtain algae comprising 8% by weight of B-carotene (here inafter "BC) at an approximately 1:1 ratio of all-trans and 9-cis BC (4.9). The algae were harvested by dislodging cen trifuges into a concentrated paste. The paste was washed to 40 remove the salt and sterilized, and then spray dried to yield Db powder comprising approximately 8% BC and less than 5% moisture. The powder was packaged in capsules of 250 mg algae containing 20 mg of BC each together with all of the natural components of the algae. The BC of the capsules 45 retains the original 1:1 ratio of isomers. The capsules are packaged in vacuum closed blisters which have a shelflife of up to three years. For the animal studies the Db powder was mixed with the diet to give 8% of Dunaliella powder in the feed. 50 EXAMPLE I
The aim of the first experiment was to study the effect of a combination treatment of fibrates and a crude Dunaliella 55
powder-rich diet on plasma apoAI and HDL cholesterol lev els.
Six month old male littermates, transgenic human apoAI mice on the background of C57BL/6 mice were used (Rubin EM, Ishida BY, Clift S M, Krauss R M. (1991) Proc Natl 60 Acad Sci USA. January 15: 88(2):434-8, Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size sub classes). The mice contain the liver-specific enhancer of the 65 human apo A-I gene promoter necessary to drive hepatic apo A-I expression. The mice (n=24) were divided into four 6 groups (n-6 in each group) and fed daily with a standard diet (Koffolk, Israel Diet no. 19510 ) ad libitum. The first group (control) was administrated with phosphate buffered saline (PBS). The second group (Fibrate) was administrated with ciprofibrate (Lipanor, CTZ, Israel), 30 mg/Kg body weight, in PBS. The third group (Dunaliella) was supplemented with PBS and crude Dunaliella powder. The fourth group was supplemented with ciprofibrate and crude Dunaliella powder, which provided ~4 g of 9-cis-B-carotene per one Kg of the diet. The mice were sacrificed after 4 weeks of treatment.
The results (FIG. 1) showed that plasma HDL cholesterol levels reached the highest levels in mice treated with both fibrate and crude Dunaliella powder (p<0.05 all pairwise multiple comparison procedures, "control group versus "ciprofibrate plus crude Dunaliella powdergroup'). The low estlevel was detected in the control group, 408-42 mg/dl., and the highest in the combination of ciprofibrate and crude Dunaliella powder treated group, 535+71 mg/dl. A similar trend, although not statistically significant, was observed in apoAI plasma levels.
EXAMPLE II
To test the effect of Dunaliella on atherogenesis, male apoE-deficient mice (n=10) were fed with standard chow diet as defined above, supplemented with 8% of crude Dunaliella powder for 6 weeks. A control group (n=10) received chow diet alone. Atherosclerosis, determined by the lesion size at the aortic sinus, was 34% lower in the group of mice treated with crude Dunaliella powder than in the control group of mice (FIG. 2) .
EXAMPLE III
To test the effect of Dunaliella powder on atherogenesis, male apoE-deficient mice (n=13) were fed a standard chow diet supplemented with 8%. Dunaliella powder for 8 weeks. A second group (n=12) was treated with oxidized Dunaliella powder, containing no B-carotene, while the control group (n=12) received chow dietalone. Atherosclerosis, determined by the lesion size at the aortic sinus, was 33% lower in Dunaliella treated group than in control group, p=0.027 (FIG.  3) . In contrast, oxidized Dunaliella powder did not affect atherogenesis.
EXAMPLE IV
To test the effect of Dunaliella on atherogenesis, male LDL receptor-deficient mice (n=10) were fed a standard chow diet supplemented with 8% Dunaliella powder for 3 weeks fol lowed by 7 weeks of Western diet. A second group was treated with oxidized Dunaliella powder (n=10) and control group (n=10) received chow diet followed by Western diet, alone. Atherosclerosis, determined by the lesion size at the aortic sinus, was 65% lower in Dunaliella treated group than in control group, p=0.004 (FIG. 4) . In contrast, oxidized Dunaliella powder did not affect atherogenesis.
EXAMPLEV
Cholesterol absorption was measured by a fecal dual-iso tope method, which measures the ratio of fecal excretion of H-sitostenol (which is not absorbed) to '''C-cholesterol (which is variably absorbed). The apoE-deficient mice were divided into 2 groups, the group of mice treated with Dunaliella was administrated with 8% of crude Dunaliella powder in chow diet for 3 weeks (n=6) and a control group 7 (n-6) received chow diet alone. Administration of crude Dunaliella powder to apoE-deficient mice resulted, (simi larly to previously described RXR agonists) in inhibition of cholesterol absorption (FIG. 5) .
EXAMPLE VI
The aim of the human trial was to study the effect of the combination offibrate and crude Dunaliella bardawill powder in patients with low HDL (<35 mg/dl) and high TG levels (>250 mg/dl).
At the first stage the patients (n=20) received fibrates (ciprofibrate or bezafibrate) for at least 3 months. At the second stage of the study the patients received 4 pills of crude Dunaliella powder according to the invention, 2 pills with breakfast and 2 pills with dinner, to provide a total daily uptake of 80 mg of B-carotene. Plasma lipid profile was detected after each stage of the study.
The results (FIG. 6) show that plasma HDL levels were significantly (p=0.002, paired t-test) higher after the com bined treatment of fibrate and crude Dunaliella powder treat ment in comparison to fibrate alone (29.3+6.8 mg/dl versus 36.5-9.9 mg/dl., respectively; a 24.5% increase).
A similar trend, although not significant (p=0.35) was observed in plasma apoAI levels, 120.9+15.2 versus 128.4+28.2 in fibrate and fibrate together with B-carotene, respectively. These findings suggest that the combined treat ment affects both apoAI synthesis and the process of reverse cholesterol transport.
EXAMPLE VII
To test the effect of Dunaliella on Diabetes, male LDL R-\-mice (n=30) were fed a Western diet (42% calories from fat) in order to induce Diabetes. After 4 weeks of Western diet feeding, the mice were divided into 6 groups (n=5 in each group) and were fed Western diet fortified by rosiglitazone (0.02% of the diet, weight/weight), crude Dunaliella powder (8% of the diet, weight/weight) or 9-cis retinoic acid (24 nmol/mousexday). The treatments lasted 4 weeks.
The 8% Dunaliella powder provided ~1.5 nmol 9-cis ret inoic acid/mousexday. This calculated amount is based on conversion off-caroteine to vitamin A (27 molecules provide
